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ABSTRACT 
Background and Purpose: Recent trials have shown the superiority of endovascular 
thrombectomy (EVT) over medical therapy alone in certain stroke patients with 
proximal arterial occlusion. Using data from REVASCAT and a parallel reperfusion 
treatment registry, we sought to assess the utilization of EVT in a defined patient 
population, comparing the outcomes of patients treated in and outside the REVASCAT 
trial.  
Methods: SONIIA, a population-based, government-mandated, prospective registry of 
reperfusion therapies for stroke encompassing the entire population of Catalonia was 
used as data source. The registry documents 5 key inclusion criteria of the REVASCAT 
trial: age, stroke severity, time to treatment, baseline functional status and occlusion 
site. We compared procedural, safety and functional outcomes in patients treated in 
and out outside the trial. 
Results:  From 11/2012 to 12/2014, out of 17596 ischemic stroke patients in Catalonia 
(population 7.5 million), 2576 patients received reperfusion therapies (17/100,000 
inhabitants-year), mainly iv thrombolysis only (2036). From the remaining 540 treated 
with EVT, 103 patients (out of 206 randomized) were treated within REVASCAT and 
437 outside the trial. Of these, 399 did not fulfill some of the study criteria, and 38 
were trial candidates (8 treated at REVASCAT centers and 30 at 2 non-REVASCAT 
centers). The majority of procedural, safety and functional outcomes were similar in 
patients treated with EVT within and outside REVASCAT.  
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Conclusions: REVASCAT enrolled nearly all eligible patients representing one-third of 
all patients treated with EVT. Patients treated with EVT within and outside REVASCAT 
had similar outcomes, reinforcing the therapeutic value of EVT.   
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INTRODUCTION 
Recent trials have shown the superiority of endovascular thrombectomy (EVT) over 
medical therapy alone in certain stroke patients with proximal arterial occlusion.1-5 The 
generalizability of these results is not yet established since these trials included 
relatively homogeneous populations of patients with moderate to severe strokes due 
to proximal occlusions in the anterior circulation. The REVASCAT (RandomizEd trial of 
reVasculArization with SOLITAIRE FR® device versus best mediCal therapy in the 
treatment of Acute stroke due to anTerior circulation large vessel occlusion presenting 
within eight-hours of symptom onset, ClinicalTrials.gov number, NCT01692379) trial5 
had information with regards to the number of patients treated outside of the trial at 
participating centers and the reasons for exclusion.  
REVASCAT investigated the benefit of mechanical thrombectomy with the Solitaire FR 
device in addition to best medical therapy (including iv tPA) compared to best medical 
therapy alone in patients with acute large vessel stroke.5 The study was undertaken in 
Catalonia (Spain) and participating centers were the 4 largest regional tertiary 
hospitals recognized by the Catalan health authorities as comprehensive stroke 
centers (CSC). In 2011, the Stroke Program of Catalonia, a health administration plan 
that seeks to improve quality of stroke care and outcomes, launched a mandatory 
registry (SONIIA) to monitor the quality of reperfusion therapies for acute ischemic 
stroke (AIS). The registry occurred in parallel with REVASCAT capturing patients within 
the exact catchment area as REVASCAT, including those treated in the trial. 
In this study we used data from the SONIIA registry and the REVASCAT trial to assess 
the utilization of EVT in a defined patient population, the reasons for exclusion of 
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patients from the REVASCAT trial, and to compare the outcomes of patients treated in 
REVASCAT with those treated outside the trial. 
 
METHODS 
Since January 2011, all AIS patients treated with any reperfusion treatment modality 
(EVT +/- iv tPA) are being entered into the SONIIA registry, a population-based, 
government-mandated, prospective database. The registry is subject to annual 
external audits to ensure completeness. Consecutive inclusion of patients in the 
SONIIA registry is annually monitored by members of the Stroke Program otherwise 
not involved in stroke care. Using data from the Hospital Discharge Database for the 
period of interest and based on specific ICD-9 diagnostic and procedure codes, we 
identify overall and by hospital ischemic stroke admissions that received any 
reperfusion therapy during admission. The Hospital Discharge Database is a health 
administration dataset used for hospital reimbursement that contains information on 
all admissions as well as the procedures performed. Stroke admissions (with 
reperfusion therapies) retrieved this way are cross-checked with the information 
available in the SONIIA registry for the same period. Undeclared cases are identified 
and hospitals requested to retrospectively include them in the registry to eventually 
have a non-biased view of the quality of reperfusion therapies performed in the 
territory defining this population of 7.5 million inhabitants.6 Hospitals with capacity to 
deliver reperfusion treatments for stroke within the stroke network of publicly 
financed centers in Catalonia include cases through a web-based tool. This network 
concentrates almost all reperfusion therapies delivered for AIS after the government 
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of Catalonia commissioned the Stroke Program to organize acute stroke care in 2006 
to cover the entire Catalan population. Data from the health-administration database 
that includes all acute hospitalizations in public and private centers show that between 
2011 and 2014, private hospitals performed 4 (0.0001%) iv thrombolyses and 3 
(0.002%) EVT out of 4266 iv thrombolyses and 1143 EVT recorded in public centers. 
Additionally, per Catalan health authorities mandated protocol, all stroke alerts with 
EMS involvement are transferred to the nearest public hospital with capacity to 
perform iv tPA. Thus, the Catalan network of public stroke treating hospitals includes: 
community hospitals operating via telestroke, primary stroke centers and CSCs. The 
first 2 hospital categories contribute to SONIIA iv thrombolysis cases only while CSCs 
perform and report data on iv tPA and EVT. In the 4 REVASCAT centers, EVT were done 
by the same teams within and outside the trial. The 2 additional centers that only 
treated patients outside the trial were also accredited as CSCs by the Catalan Health 
Authorities and used similar protocols (we provide details of the procedures in the 
results).     
The registry is linked to the Health Insurance Population Registry of Catalonia which is 
universally available for all residents so that once the Health ID is entered the system 
automatically retrieves all socio-demographic data available for that person. Inclusion 
of non-insured (non-residents) people is also performed in every case. After having 
satisfied this initial step, stroke neurologists are required to enter a basic set of clinical, 
neuroimaging and outcome variables at baseline, 24-36 hours and at 3 months.6  
The SONIIA registry satisfies all legal requirements mandated by the local law 
regarding protection of personal data. All patients or their surrogate provided written 
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informed consent before the endovascular procedure (whether experimental or 
routine) and data entry in the registry. 
Ascertainment of REVASCAT eligibility and failures of enrollment  
Throughout the REVASCAT trial, patients randomized to the active arm of the trial 
were also included in the SONIIA registry as were all patients treated with EVT under 
routine practice. In order to guarantee that their participation in the trial was fully 
masked, the registry did not include any information to identify patients as REVASCAT 
ones. We used the registry as a data source for regularly monitoring the number of 
EVT patients who satisfied basic REVASCAT entry criteria. By comparing that number to 
the number of patients randomized in the active arm (randomization ratio: 1:1), we 
obtained periodic estimates of the number of patients enrolled into the active arm 
versus potentially eligible but treated outside of the trial. The registry coordinator 
attended the REVASCAT steering committee meetings regularly to give feedback on 
the proportion of EVT patients eligible for REVASCAT identified through the registry.  
Once the REVASCAT steering committee decided to terminate the trial based on the 
DSMB recommendation, we used registry data to identify all patients that underwent 
EVT within the REVASCAT period (24/Nov/2012-12/Dec/2014) at the 6 hospitals 
performing EVT in Catalonia. We then applied REVASCAT inclusion criteria to the whole 
sample to identify all eligible patients both at REVASCAT participating hospitals and 
non-REVASCAT centers. The REVASCAT inclusion criteria applicable to the registry data 
were: 1) age ≥ 18, ≤ 80; 2) prestroke modified Rankin scale score 0 or 1; 3) stroke 
severity measured with the National Institutes of Health Stroke Scale (NIHSS) before 
angiography ≥ 6; 4) intracranial ICA (distal ICA or T occlusions), M1 or tandem 
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occlusions with a pre-treatment mTICI score 0 or 1; and 5) time from last seen to groin 
puncture ≤ 8 hours.5 Since the age criterion was amended in June 2014, we adapted 
our search algorithm accordingly. Every 3 months throughout the trial, in preparation 
for the upcoming steering committee meeting, the list of cases retrieved by this search 
algorithm was identified using the anonymous registry ID number and forwarded to 
each REVASCAT hospital. Authorized local investigators reviewed each case in the list 
preserving anonymity rights and sent back aggregated information about the number 
of REVASCAT-endovascular cases in the list and reasons for exclusion among the 
remaining REVASCAT eligible (non-randomized) patients. These anonymized cases 
were reviewed at each REVASCAT steering committee meeting to ensure compliance 
with enrollment. Importantly, we were aware that using registry data to detect 
REVASCAT eligible cases could overestimate the number of patients who met the 
inclusion criteria because some relevant clinical and neuroimaging features (e.g. lab 
deviations, pre-treatment ASPECTS score, etc.) were not recorded in the registry. 
For exploratory analysis comparing the safety and efficacy of thrombectomy in and 
outside the trial, we defined several subgroups of patients that differed from patients 
treated in REVASCAT in only one criterion and a group of patients that differed in more 
than one criterion.  
Statistical analysis 
We utilized descriptive statistics. All analyses were performed with STATA 11.1.  
 
RESULTS 
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Within the REVASCAT enrollment period (roughly two years), 17596 ischemic strokes 
occurred in Catalonia. Of these, 206 patients were included in the trial (103 in each 
arm) and 2576 AIS patients received reperfusion therapies, resulting in an aggregated 
reperfusion treatment rate of 17/100,000 inhabitants-year (15.6% of all AIS admissions 
within the study period). Of those, 2036 (79%) received iv thrombolysis only and the 
remaining 540 (21%) underwent EVT (combined iv tPA+EVT: 260 cases). Figure 1 shows 
a flow chart of EVT patients treated in Catalonia during REVASCAT, of whom 464 (86%) 
were treated at REVASCAT hospitals.  
Reasons for exclusion from the trial 
According to registry data, among 437 EVT performed outside REVASCAT, 340 were 
ineligible. Reasons for ineligibility were: treatment later than 8h (n=75), age criteria 
(n=33), M2 occlusion (n=36), basilar artery occlusion (n=27), patients with differences 
in more than one of these inclusion criteria (n=97) and a heterogeneous group (n=72) 
of patients with mild strokes, poor functional status before the qualifying stroke 
and/or extracranial or distal intracranial occlusions. Of the 97 apparently eligible 
patients, 30 were treated at non-REVASCAT hospitals and 67 in REVASCAT hospitals. In 
the latter, 59 had additional reasons for ineligibility not captured by SONIIA: different 
occlusion site (n=19), comorbidity not recorded in the registry (n=12), patient unlikely 
to be available for follow-up (n=7), informed consent not available (n=6), last time 
seen well not well determined (n=6), other clinical conditions (n=6) and low ASPECTS 
score (n=3). Thus, the number of patients that eluded randomization was 8/214 (3.7%) 
at REVASCAT centers and 38/244 (15.6%) in the entire study population.  
Characteristics of patients treated in and outside the trial 
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We explored the characteristics of patients included in the trial and those in the main 
subgroups of patients excluded from the trial (Table 1). The main baseline differences 
were those derived by the definition of the exclusion criteria (i.e., patients over 80 had 
higher average age) and the subgroups (i.e., patients in the older age category had 
lower proportion of mRS 0 before stroke, or patients in the M2 occlusion group had 
lower baseline severity). Table 1 shows that EVT modalities and procedural results 
were similar for patients inside and outside the trial, including door to puncture times. 
Regarding safety outcomes, there were a few more hemorrhages in the M2 and basilar 
groups, but the absolute numbers were low. Mortality was only increased in the 
basilar group and was rather low in some of the other subgroups. The 3-month 
functional outcomes were similar in most groups of patients treated with 
thrombectomy and superior to those seen in the medical arm of the REVASCAT trial 
(Figure 2).  
 
DISCUSSION 
In this report, we provide information about the extent to which REVASCAT findings 
are valid in the overall population studied (the Catalan population) and an estimate of 
potential eligible patients for EVT within a defined study population over a two-year 
period. The inclusion of the vast majority of eligible patients within the target 
population supports the validity of REVASCAT for the whole Catalan population 
because the majority of the treatments were performed in REVASCAT centers. The 
observed similar safety results in patients treated in and outside REVASCAT is 
reassuring for the routine use of mechanical thrombectomy. Furthermore, our findings 
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suggest that applying similar indications of mechanical thrombectomy as those used in 
Catalonia during REVASCAT might increase the number of patients who benefit from 
thrombectomy by up to 3 times of those included in the recently published trials.  
While undoubtedly representing the most valid form of data generation for comparing 
treatments, randomized trials can lack broad generalizability. Linking randomized trials 
to registries is thought to represent a novel, improved form of evidence generation 
that combines the advantages of methodological rigor imposed by randomized trials 
with applicability of findings to larger population conferred by registries.7 This 
information distinguishes REVASCAT from previous trials and addresses one major 
remaining concern related to EVT for stroke: that of applicability in general practice.  
We believe that our findings are highly relevant for further planning of stroke systems 
of care since due to the dramatic benefit of EVT demonstrated by the recent 
randomized trials in very selected populations, endovascular stroke therapy is likely to 
be widely adopted by multiple health care systems around the world. In that respect, 
given the 540 patients treated over two years in a population of 7.5 million, to which 
the 103 patients randomized to control in REVASCAT should be added, we estimate a 
current EVT utilization rate of 4.3/100,000 inhabitants-year, roughly 4% of all AIS 
admissions during the trial (17596). This figure will likely increase in the future in view 
of the mounting evidence of dramatic benefit with EVT. 
Outcomes were similar across different patient subgroups, which reinforces the value 
of mechanical thrombectomy in a wide range of stroke patients not necessarily 
fulfilling all the inclusion criteria of recent trials. The functional outcome assessment in 
the SONIIA registry was neither blinded nor done centrally with a video recording of 
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the mRS assessment as in the trial, but the strong correlation of video based 
assessments in REVASCAT with the assesments performed by the same personel 
performing assessments in SONNIA (ref. 8 Lopez-Cancio et al) suggests that differences 
in the mRS assessment cannot account for the better outcomes in patients treated 
with EVT outside the trial compared to control patients in REVASCAT. In summary, it is 
likely that other patients do benefit from thrombectomy as long as the treatment is 
done as in the recent endovascular trials using stentriever devices and treating 
patients as expeditely as possible. However, it is necessary to remark also that for the 
same reason these results refer mainly to treatments performed at high volume CSCs 
with extensive experience and proven capabilities in all aspects of the complex AIS 
patient care. 
In addition, we believe that the existence of a concurrent, mandatory registry allowing 
feed-back regarding rates of patients treated outside of the trial, along with equipoise 
among all investigators have been key ingredients to ensuring such high enrollment 
rates in REVASCAT. This trial enrolled 206 patients at four centers over 2 years, yielding 
a rate of 2.1 patients/center/month, the highest recruitment rate of all other 
randomized endovascular trials.  
This study is not without limitations. Given that our registry only captures patients 
treated with reperfusion therapies, it is difficult to estimate the proportion of 
untreated patients that would have satisfied REVASCAT entry criteria. However, since 
Catalonia has a well organized system of acute stroke care with good access to expert 
care throughout the entire region, we estimate it to be low. The low number of 
REVASCAT eligible patients treated outside the trial provides evidence of no further 
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concealed selection criteria within the trial, but we cannot guarantee that patients 
that did not meet REVASCAT eligibility criteria were not selected for EVT according to 
other prognostic criteria. Finally, for the sake of simplicity, our registry sacrificed a 
number of variables, including ASPECTS score. Patients with low ASPECTS scores were 
generally excluded from treatment, and for this reason our study does not provide 
evidence about the treatment of patients with different characteristics, such as large 
ischemic cores. The absence of information such as ASPECTS scores also posed further 
difficulties at the time of determining trial eligibility, which could only be addressed at 
REVASCAT participating centers. Since all patients treated at non REVASCAT centers 
and satisfying basic REVASCAT inclusion criteria were considered trial eligible, the 
15.6% calculated is likely to overestimate the proportion of truly eligible patients 
treated outside the trial in the whole population.  
In conclusion, this study provides further evidence of the benefit of EVT seen in recent 
mechanical thrombectomy trials. The inclusion of most eligible patients in the trial 
shows that there was no major bias during the conduction of the REVASCAT trial, and 
the similar outcomes in patients not fulfilling all the inclusion criteria in REVASCAT 
suggests that EVT may be beneficial for a wider range of patients when it is performed 
in experienced centers.  
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FIGURE LEGENDS 
Figure 1. Flow chart of EVT performed throughout the REVASCAT trial. 
 
 
Figure 2. Functional outcome of different subgroups of patients treated in and outside 
the REVASCAT trial.  
 
The vertical line indicates de proportion of patients with mRS 0 to 2 in the medical arm 
of the REVASCAT trial. With the exception of an excess of mortality in patients with 
basilar occlusion, the distribution of mRS scores is favorable in all subgroups of 
patients treated with EVT compared to patients randomized to the control arm in 
REVASCAT. 
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Table 1. Characteristics of the REVASCAT trial patients and other patients treated outside the trial.  
 Randomize
d Control 
(n=103) 
Randomized 
EVT 
(n=103) 
Apparently 
eligible, not 
randomized 
(N=97) 
Older than 
age cutoff 
 (n=33) 
M2 occlusion 
(n=36) 
Basilar 
occlusion 
(n= 27) 
OTP > 8 h 
(n=75) 
> 1 
difference 
(n=97) 
Miscelanea 
(n=72) 
Age, mean (SD)  67.2 (9.5) 65.7 (11.3) 62.8 (14) 83 (1.6) 67.1 (10.6) 66.4 (15.2) 64.1 
(13.2) 
71.2 (13.5) 65.9 (13.7) 
Sex, women 49 (47.6) 48 (46.6) 38 (39.2) 20 (60.6) 16 (44.4) 8 (29.6) 41 (54.7) 45 (46.4) 29 (40.3) 
Pre morbid mRS          
0 83 (80.6) 86 (83.5) 82 (84.5) 23 (69.7) 30 (83.3) 25 (92.6) 63 (84) 51 (52.6) 49 (68.1) 
1 20 (19.4) 17 (16.5) 15 (15.5) 10 (30.3) 6 (16.7) 2 (7.4) 12 (16) 15 (15.5) 7 (9.7) 
Baseline NIHSS, 
median (IQR)  
17 (12-19) 17 (14-20) 18 (14-20) 16 (12-21) 13 (10-20) 27 (14-35) 16 (13-20) 13 (7-21) 16 (12-21) 
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Occlusion site          
ICA-T  27 (26.7)  26 (25.5) 22 (22.7) 11 (29) - - 10 (13.3) 4 (4.1) 7 (9.7) 
M1 MCA 65 (64.4)  66 (64.7) 49 (50.5) 21 (55.3) - - 50 (66.7) 10 (10.3) 35 (48.6) 
Tandem 
occlusions 
13 (12.9)  19 (18.6) 26 (26.8) 4 (12.1) - - 15 (20) 3 (3.1) 6 (8.3) 
Treatment 
modality 
         
Mechanical  
thrombectomy 
 97 (94.2) 87 (89.7) 30 (90.9) 30 (83.3) 22 (81.5) 70 (93.3) 84 (86.6) 63 (87.5) 
Thrombectomy 
+ IA 
thrombolysis 
 1 (1.0) 8 (8.3) 3 (9.1) 4 (11.1) 4 (14.8) 3 (4) 5 (5.2) 2 (2.8) 
IA thrombolysis  0 1 (1) 0 2 (5.6) 1 (3.7) 0 3 (3.1) 1 (1.4) 
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Diagnostic-only 
angiography 
 5 (4.8) 1 (1) 1 (2.6) 0 0 2 (2.7) 5 (5.2) 6 (8.3) 
OTP min, 
median (IQR) 
 269 (201, 340) 223 (165-305) 220 
(150,305) 
222 (175-
287) 
310 (220-
375) 
693 (577-
885) 
590 (261-
798) 
196 (148-270) 
DTP min, 
median (IQR) 
 110 (87-167) 115 (78-165) 84 (65-130) 148 (115-
190) 
117 (65-168) 109 (84-
145) 
125 (81-180) 118 (80-167) 
Post procedure 
mTICI 2b, 3†  
 82 (79.6) 78 (80.4) 25 (75.8) 29 (80.6) 21 (77.8) 59 (78.7) 76 (78.4) 60 (83.3) 
Procedural 
complications 
         
Distal 
embolization 
 5 (4.9) 2 (2.1) 2 (6.1) 0 0 2 (2.7) 1 (1) 1 (1.4) 
Arterial 
dissection 
 4 (3.9) 4 (4.1) 0 0 1 (3.7) 4 (5.3) 3 (3.1) 1 (1.4) 
22 
Arterial 
perforation 
 5 (4.9) 0 0 0 2 (7.4) 0 3 (3.1) 0 
Other  16 (15.5) 9 (9.3) 2 (6.1) 3 (8.3) 1 (3.7) 2 (2.7) 3 (3.1) 6 (8.3) 
sICH (SITS-
MOST) 
1.9 2 (1.9) 2 (2.1) 0 2 (5.6) 2 (7.4) 2 (2.7) 3 (3.1) 1 (1.4) 
Death at 3 
months 
15.5 19 (18.4) 16 (16.5) 7 (21.2) 2 (5.6) 12 (44.4) 7 (9.3) 20 (20.6) 7 (9.7) 
Numbers express N (%) unless otherwise stated. mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; ICA-T: Internal 
carotid artery terminus; M1 MCA: M1 segment of the middle cerebral artery; OTP: onset to puncture time; DTP: door to puncture time; TICI: 
Thrombolysis in cerebral ischemia; sICH: symptomatic intracerebral hemorrhage; SITS-MOST: Safe Implementation of Thrombolysis in Stroke-
Monitoring Study. † According to local investigators. 
